Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients

A retrospective study

P. Razzore, A. Colao, R. Baldelli, D. Gaia, P. Marzullo, E. Ferretti, D. Ferone, M. L. Jaffrain-Rea, G. Tamburrano, G. Lombardi, F. Camanni, Enrica Ciccarelli

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

OBJECTIVE: We analysed the effects of 6-months' treatment with octreotide s.c. and lanreotide-SR on circulating GH and IGF-I levels in acromegaly. DESIGN: Open retrospective study. PATIENTS: Thirty-eight patients with active acromegaly (plasma IGF-1 levels greater than 2 standard deviations for age-matched controls and increased serum GH levels not suppressible by oral glucose load) were studied. All patients received s.c. octreotide at a dose of 150-600 μg/day for six months as first therapy and subsequently, lanreotide i.m., 30-60 mg either at 14 or 10 day intervals, for 6 months. A 3 months' washout was applied before starting lanreotide treatment. MEASUREMENTS: Mean serum GH levels (from three samples), IGF-1, and clinical examination were performed before and 30, 60, 90 and 180 days after octreotide and lanreotide treatments. Safety tests, HbA1c and, thyroid function were evaluated every three months. RESULTS: Circulating GH and IGF- 1 levels were significantly reduced (P

Original languageEnglish
Pages (from-to)159-164
Number of pages6
JournalClinical Endocrinology
Volume51
Issue number2
DOIs
Publication statusPublished - 1999

Fingerprint

Octreotide
Insulin-Like Growth Factor I
Retrospective Studies
Acromegaly
Thyroid Function Tests
Therapeutics
Serum
Safety
Glucose
lanreotide

ASJC Scopus subject areas

  • Endocrinology

Cite this

Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients : A retrospective study. / Razzore, P.; Colao, A.; Baldelli, R.; Gaia, D.; Marzullo, P.; Ferretti, E.; Ferone, D.; Jaffrain-Rea, M. L.; Tamburrano, G.; Lombardi, G.; Camanni, F.; Ciccarelli, Enrica.

In: Clinical Endocrinology, Vol. 51, No. 2, 1999, p. 159-164.

Research output: Contribution to journalArticle

Razzore, P, Colao, A, Baldelli, R, Gaia, D, Marzullo, P, Ferretti, E, Ferone, D, Jaffrain-Rea, ML, Tamburrano, G, Lombardi, G, Camanni, F & Ciccarelli, E 1999, 'Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: A retrospective study', Clinical Endocrinology, vol. 51, no. 2, pp. 159-164. https://doi.org/10.1046/j.1365-2265.1999.00812.x
Razzore, P. ; Colao, A. ; Baldelli, R. ; Gaia, D. ; Marzullo, P. ; Ferretti, E. ; Ferone, D. ; Jaffrain-Rea, M. L. ; Tamburrano, G. ; Lombardi, G. ; Camanni, F. ; Ciccarelli, Enrica. / Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients : A retrospective study. In: Clinical Endocrinology. 1999 ; Vol. 51, No. 2. pp. 159-164.
@article{cb42ea18096145c8b0db29b76d35af75,
title = "Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: A retrospective study",
abstract = "OBJECTIVE: We analysed the effects of 6-months' treatment with octreotide s.c. and lanreotide-SR on circulating GH and IGF-I levels in acromegaly. DESIGN: Open retrospective study. PATIENTS: Thirty-eight patients with active acromegaly (plasma IGF-1 levels greater than 2 standard deviations for age-matched controls and increased serum GH levels not suppressible by oral glucose load) were studied. All patients received s.c. octreotide at a dose of 150-600 μg/day for six months as first therapy and subsequently, lanreotide i.m., 30-60 mg either at 14 or 10 day intervals, for 6 months. A 3 months' washout was applied before starting lanreotide treatment. MEASUREMENTS: Mean serum GH levels (from three samples), IGF-1, and clinical examination were performed before and 30, 60, 90 and 180 days after octreotide and lanreotide treatments. Safety tests, HbA1c and, thyroid function were evaluated every three months. RESULTS: Circulating GH and IGF- 1 levels were significantly reduced (P",
author = "P. Razzore and A. Colao and R. Baldelli and D. Gaia and P. Marzullo and E. Ferretti and D. Ferone and Jaffrain-Rea, {M. L.} and G. Tamburrano and G. Lombardi and F. Camanni and Enrica Ciccarelli",
year = "1999",
doi = "10.1046/j.1365-2265.1999.00812.x",
language = "English",
volume = "51",
pages = "159--164",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients

T2 - A retrospective study

AU - Razzore, P.

AU - Colao, A.

AU - Baldelli, R.

AU - Gaia, D.

AU - Marzullo, P.

AU - Ferretti, E.

AU - Ferone, D.

AU - Jaffrain-Rea, M. L.

AU - Tamburrano, G.

AU - Lombardi, G.

AU - Camanni, F.

AU - Ciccarelli, Enrica

PY - 1999

Y1 - 1999

N2 - OBJECTIVE: We analysed the effects of 6-months' treatment with octreotide s.c. and lanreotide-SR on circulating GH and IGF-I levels in acromegaly. DESIGN: Open retrospective study. PATIENTS: Thirty-eight patients with active acromegaly (plasma IGF-1 levels greater than 2 standard deviations for age-matched controls and increased serum GH levels not suppressible by oral glucose load) were studied. All patients received s.c. octreotide at a dose of 150-600 μg/day for six months as first therapy and subsequently, lanreotide i.m., 30-60 mg either at 14 or 10 day intervals, for 6 months. A 3 months' washout was applied before starting lanreotide treatment. MEASUREMENTS: Mean serum GH levels (from three samples), IGF-1, and clinical examination were performed before and 30, 60, 90 and 180 days after octreotide and lanreotide treatments. Safety tests, HbA1c and, thyroid function were evaluated every three months. RESULTS: Circulating GH and IGF- 1 levels were significantly reduced (P

AB - OBJECTIVE: We analysed the effects of 6-months' treatment with octreotide s.c. and lanreotide-SR on circulating GH and IGF-I levels in acromegaly. DESIGN: Open retrospective study. PATIENTS: Thirty-eight patients with active acromegaly (plasma IGF-1 levels greater than 2 standard deviations for age-matched controls and increased serum GH levels not suppressible by oral glucose load) were studied. All patients received s.c. octreotide at a dose of 150-600 μg/day for six months as first therapy and subsequently, lanreotide i.m., 30-60 mg either at 14 or 10 day intervals, for 6 months. A 3 months' washout was applied before starting lanreotide treatment. MEASUREMENTS: Mean serum GH levels (from three samples), IGF-1, and clinical examination were performed before and 30, 60, 90 and 180 days after octreotide and lanreotide treatments. Safety tests, HbA1c and, thyroid function were evaluated every three months. RESULTS: Circulating GH and IGF- 1 levels were significantly reduced (P

UR - http://www.scopus.com/inward/record.url?scp=0032795782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032795782&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2265.1999.00812.x

DO - 10.1046/j.1365-2265.1999.00812.x

M3 - Article

VL - 51

SP - 159

EP - 164

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 2

ER -